Loading…
SMMT
Summit Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology
$13.73-4.19%
Key metrics
- Market cap
- $10.95B
- P/E
- —
- Forward P/E
- —
- P/B
- 17.3x
- Dividend yield
- —
- EPS
- -$1.06
- ROE
- -192.50%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -1.24
- 52-week high
- $29.23
- 52-week low
- $12.07
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- 265
- Miami, United States
Company description provided by Yahoo Finance.